<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295984</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462444</org_study_id>
    <secondary_id>NCI-06-C-N033</secondary_id>
    <nct_id>NCT00295984</nct_id>
    <nct_alias>NCT00339755</nct_alias>
  </id_info>
  <brief_title>Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma</brief_title>
  <official_title>Treatment of Classical Kaposi Sarcoma With Nicotine Dermal Patch: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Nicotine may stimulate the immune system to kill Kaposi's sarcoma cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects and how well the nicotine skin&#xD;
      patch works in treating patients with Kaposi's sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the toxicity and efficacy of transdermal nicotine applied to lesions in&#xD;
           patients with classic Kaposi's Sarcoma.&#xD;
&#xD;
      OUTLINE: This is a double-blind, placebo-controlled study.&#xD;
&#xD;
      Patients apply a nicotine dermal patch to a selected lesion and a placebo patch to the other&#xD;
      lesion, replacing the same type of fresh patch every other day, during the first 2 weeks,&#xD;
      increasing the nicotine dose in week 3 and again in week 5 for a total of 15 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response at weeks 9 and 15</measure>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven classic Kaposi's sarcoma (KS)&#xD;
&#xD;
          -  At least 2 KS lesions that can be measured (minimum diameter 0.5 cm to maximum&#xD;
             diameter 3 cm) and located on body sites (leg, arm, torso, dorsum of foot or hand) to&#xD;
             which a patch can be applied&#xD;
&#xD;
               -  A third measurable lesion (if available) of the same size can be located on any&#xD;
                  body site&#xD;
&#xD;
          -  KS lesions must be separated by at least 8.0 cm at their centers and 6.0 cm at closest&#xD;
             edges&#xD;
&#xD;
          -  Patient must be a nonsmoker&#xD;
&#xD;
               -  No smoking, chewing, or other use of tobacco within the past year&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  HIV antibody negative&#xD;
&#xD;
          -  Willing to shower or bathe no more than every other day&#xD;
&#xD;
          -  No life-threatening conditions&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Chronic conditions (e.g., hypertension or diabetes) must be stable and well controlled&#xD;
&#xD;
          -  No history of HIV/AIDS, unstable angina pectoris, or claudication&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior biopsy of the selected KS lesion(s) within the past 90 days&#xD;
&#xD;
          -  No prior systemic therapy for KS within the past 90 days&#xD;
&#xD;
          -  No concurrent systemic or local conventional treatment for KS&#xD;
&#xD;
          -  No prior use of a nicotine product within the past year&#xD;
&#xD;
          -  No prior surgery, chemotherapy, biologic therapy, or radiotherapy within the past 90&#xD;
             days&#xD;
&#xD;
          -  No prior organ allograft&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J. Goedert, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goedert JJ, Scoppio BM, Pfeiffer R, Neve L, Federici AB, Long LR, Dolan BM, Brambati M, Bellinvia M, Lauria C, Preiss L, Boneschi V, Whitby D, Brambilla L. Treatment of classic Kaposi sarcoma with a nicotine dermal patch: a phase II clinical trial. J Eur Acad Dermatol Venereol. 2008 Sep;22(9):1101-9. doi: 10.1111/j.1468-3083.2008.02720.x. Epub 2008 Apr 1.</citation>
    <PMID>18384551</PMID>
  </results_reference>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>classic Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

